Abbott’s SIMCOR ® ( niacin extended-release / sim­vas­tatin ) Receives FDA Approval for New Dosage Strengths
Abbott today received U.S. Food and Drug Admin­is­tra­tion approval for two new dosage strengths of SIMCOR®, a cho­les­terol med­ica­tion.  The new SIMCOR dosage strengths com­bine 40 mg of sim­vas­tatin â the most com­monly pre­scribed dose of sim­vas­tatin â with either 500 mg or 1,000 mg of niacin extended-release.  SIMCOR is the first treat­ment to com­bine Abbott’s pro­pri­etary niacin extended-release …

Read more on PR Newswire via Yahoo! Finance